Esperion loss grows as sales effort ramps up
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) reported a loss of $90.8 million or $3.50 a share in the first quarter ended March 31, vs. a loss of $78.2 million or …
Nexletol combo cuts bad cholesterol 60.5 percent in new study
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR), the Ann Arbor-based developer of cholesterol-lowering drugs, announced that the results of a Phase 2 study evaluating the combination of its Nexletol (bempedoic acid) …
Esperion appoints new COO; commercial officer leaves
ANN ARBOR—Esperion Therapeutics Inc. has named veteran cardiovascular pharmaceutical industry executive Sheldon Koenig as its chief operating officer. Koenig will report to president and CEO Tim M. Mayleben. In this …
New cholesterol-buster from Esperion now available in U.S.
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ: ESPR), developers of novel treatments to reduce cholesterol in the bloodstream, announced the United States commercial availability of Nexlizet tablets. Nexlizet is a combination of …
Esperion reports first financial results since new cholesterol drug approval
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ:ESPR) reported a loss of $78.2 million or $2.84 a share in the first quarter of 2020, vs. net income of $87.4 million or $3.07 a …
Esperion gets Japanese manufacturer for new cholesterol-buster
ANN ARBOR—Esperion Therapeutics Inc. announced a collaboration agreement with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of Nexletol and Nexlizet tablets in Japan. Both medicines were recently approved …
Esperion names pharma CFO to board
ANN ARBOR—The Ann Arbor cholesterol-lowering drug developer Esperino Therapeutics Inc. (NASDAQ: ESPR) announced the appointment of Alan Fuhrman as a Class III director, with a term expiring at the 2022 …
Esperion gets FDA OK for another new cholesterol-buster, offers financial update
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) announced U.S. Food and Drug Administration approval of Nexlizet, a combination tablet of Esperion’s new non-statin cholesterol reducing drug bempedoic acid and an earlier …